MET Gene Copy Number Alterations and Expression of MET and Hepatocyte Growth Factor Are Potential Biomarkers in Angiosarcomas and Undifferentiated Pleomorphic Sarcomas

Cancer statistics, 2014

(2014) Rebecca Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update

(2013) Antonio C. Wolff et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized Phase II Trial of Onartuzumab in Combination With Erlotinib in Patients With Advanced Non–Small-Cell Lung Cancer

(2013) David R. Spigel et al.   JOURNAL OF CLINICAL ONCOLOGY

Treatment Rationale Study Design for the MetLung Trial: A Randomized, Double-Blind Phase III Study of Onartuzumab (MetMAb) in Combination With Erlotinib Versus Erlotinib Alone in Patients Who Have Received Standard Chemotherapy for Stage IIIB or IV Met-Positive Non–Small-Cell Lung Cancer

(2012) David R. Spigel et al.   Clinical Lung Cancer

Definition of a fluorescence in-situ hybridization score identifies high- and low-level FGFR1 amplification types in squamous cell lung cancer

(2012) Hans-Ulrich Schildhaus et al.   MODERN PATHOLOGY

Activating mutation in MET oncogene in familial colorectal cancer

(2011) Deborah W Neklason et al.   BMC CANCER

Prognostic significance of overexpression of c-Met oncoprotein in cholangiocarcinoma

(2011) M Miyamoto et al.   BRITISH JOURNAL OF CANCER

A Phase I Dose-Escalation Study of Tivantinib (ARQ 197) in Adult Patients with Metastatic Solid Tumors

(2011) L. S. Rosen et al.   CLINICAL CANCER RESEARCH

Activated MET Is a Molecular Prognosticator and Potential Therapeutic Target for Malignant Peripheral Nerve Sheath Tumors

(2011) K. E. Torres et al.   CLINICAL CANCER RESEARCH

MET Signaling Pathway: A Rational Target for Cancer Therapy

(2011) Leonard J. Appleman   JOURNAL OF CLINICAL ONCOLOGY

Inhibition of phosphorylated c-Met in rhabdomyosarcoma cell lines by a small molecule inhibitor SU11274

(2011) Jinxuan Hou et al.   Journal of Translational Medicine

Gene amplification and protein overexpression of MET are common events in ovarian clear-cell adenocarcinoma: their roles in tumor progression and prognostication of the patient

(2011) Sohei Yamamoto et al.   MODERN PATHOLOGY

Postradiation cutaneous angiosarcoma after treatment of breast carcinoma is characterized by MYC amplification in contrast to atypical vascular lesions after radiotherapy and control cases: clinicopathological, immunohistochemical and molecular analysis of 66 cases

(2011) T Mentzel et al.   MODERN PATHOLOGY

Identification of the Receptor Tyrosine Kinase c-Met and Its Ligand, Hepatocyte Growth Factor, as Therapeutic Targets in Clear Cell Sarcoma

(2010) I. J. Davis et al.   CANCER RESEARCH

Functional Mapping of Receptor Tyrosine Kinases in Myxoid Liposarcoma

(2010) T. Negri et al.   CLINICAL CANCER RESEARCH

Novel Therapeutic Inhibitors of the c-Met Signaling Pathway in Cancer

(2009) J. P. Eder et al.   CLINICAL CANCER RESEARCH

EGFR fluorescence in situ hybridisation assay: guidelines for application to non-small-cell lung cancer

(2009) M Varella-Garcia et al.   JOURNAL OF CLINICAL PATHOLOGY

Therapeutic potential of hepatocyte growth factor/scatter factor neutralizing antibodies: Inhibition of tumor growth in both autocrine and paracrine hepatocyte growth factor/scatter factor:c-Met-driven models of leiomyosarcoma

(2009) C.-F. Gao et al.   MOLECULAR CANCER THERAPEUTICS